Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Overview

Main trials

HD1 (for early, intermediate and advanced stages respectively)

In the HD1 trial (stage IA-IIIA with RF), two radiotherapy concepts were compared (2 x COPP/ABVD + 40 Gy EF vs. 2 x COPP/ABVD + 20 Gy EF + 20 Gy on bulk).

HD2 (for early, intermediate and advanced stages respectively)

In the HD2 trial (stage IIIA without RF), sole radiotherapy with 40 Gy TNI was compared to 3 x COPP/ABVD plus radiotherapy (20 Gy IF + 40 Gy on residual tumor).

HD3 (for early, intermediate and advanced stages respectively)

In the HD3 trial (stage IIIB, IV), all patients received 3 cycles of COPP/ABVD, and then different therapeutic approaches depending on the response to that treatment were compared to each other. In case of a complete remission (CR), a radiotherapy (20 Gy IF) was compared to another cycle of COPP/ABVD. If no CR was present, treatment depended on the involved sites: either radiotherapy (nodular involvement, 20 Gy IF + 40 Gy on residual tumor) or chemotherapy (disseminated involvement, 4 x CEVD).

HD4 (early stages)

In the HD4 trial, two radiotherapy concepts were compared to each other (40 Gy EF vs. 30 Gy EF + 10 Gy IF).
(publication on the HD4 trial

HD5 (intermediate stages)

In the HD5 trial (stage I, II with RF, stage IIIA), 2 x COPP/ABVD were compared to 2 x COPP/ABV/IMEP, followed by radiotherapy with 30 Gy EF (10 Gy on bulk).
(publication on the HD5 trial

HD6 (advanced stages)

In the HD6 trial (stage IIIB, IV), 4 x COPP/ABVD were compared to 4 x COPP/ABV/IMEP, followed by radiotherapy with 30 or 40 Gy (on bulk or residual tumor).
(publication on the HD6 trial

HD7 (early stages)

In the HD7 trial (stage I, II without RF) 2 x ABVD + 30 Gy EF + 10 Gy IF were compared to sole radiotherapy (30 Gy EF + 10 Gy IF).
(publication on the HD7 trial

HD8 (intermediate stages)

In the HD8 trial, two radiotherapy concepts were compared to each other. Following 2 x COPP/ABVD, patients received either 30 Gy EF (10 Gy on bulk) or 30 Gy IF (10 Gy on bulk).
(publication on the HD8 trial

HD9 (advanced stages)

In the HD9 trial, 4 x COPP/ABVD, 8 x baseline BEACOPP and 8 x escalated BEACOPP were compared to each other. Afterwards, radiotherapy was administered if necessary (30 Gy on bulk, 40 Gy on residual tumor)
(publication on the HD9 trial

HD10 (early stages)

In the HD10 trial (early stages), two chemotherapies (4 x ABVD vs. 2 x ABVD) and two radiotherapy concepts (30 Gy IF vs. 20 Gy IF) were compared to each other.
(publication on the HD10 trial

HD11 (intermediate stages)

In the HD11 trial (intermediate stages), two chemotherapies (4 x ABVD vs. 4 x baseline BEACOPP) and two radiotherapy concepts (30 Gy IF vs. 20 Gy IF) were compared to each other.
(publication on the HD11 trial

HD12 (advanced stages)

In the HD12 trial (advanced stages), two chemotherapies (8 x escalated BEACOPP vs. 4 x escalated BEACOPP + 4 baseline BEACOPP) plus either no radiotherapy or 30 Gy on bulk + 30 Gy on residual tumor were compared to each other.
(publication on the HD12 trial

HD13 (early stages)

In the HD13 trial, ABVD, ABV, AVD or AV (2 cycles respectively) plus subsequent 30 Gy IF radiotherapy, were compared to each other.
(publication on the HD13 trial

HD14 (intermediate stages)

In the HD14 trial, 4 x ABVD plus 30 Gy IF-RT were compared to 2 x escalated BEACOPP and 2 cycles of ABVD plus 30 Gy IF-RT.
(publication on the HD14 trial

HD15 (advanced stages)

In the HD15 trial, 8 x escalated BEACOPP were compared to 6 x escalated BEACOPP and 8 x BEACOPP 14. After end of chemotherapy, a PET examination was performed, and PET-positive residual tumors larger than 2.5 cm were irradiated.
(publication on the HD15 trial)

HD16 (early stages)

This multicenter, randomized phase III trial evaluated a stratification of treatment in early stage patients. All patients received 2 cycles of ABVD after which a PET examination was performed. In the standard arm, patients received radiotherapy with 20 Gy IF. In the experimental arm, PET-positive patients also received 20 Gy IF radiotherapy, but PET-negative patients were not irradiated.

HD18 (advanced stages)

In this trial it was to be demonstrated that the experimental treatment (8 x escalated BEACOPP + rituximab) in patients who are PET-positive after 2 cycles of chemotherapy is superior to standard treatment (8 x escalated BEACOPP) with respect to the primary endpoint (PFS). Further, it was to be shown that the experimental treatment (4 x escalated BEACOPP) in patients who are PET-negative after 2 cycles of chemotherapy is non-inferior to standard treatment (8 x escalated BEACOPP) with respect to the primary endpoint (PFS).

Trials on relapsed Hodgkin lymphoma

HD-R1

The HD-R1 evaluated whether Hodgkin lymphoma patients benefit from high-dose chemotherapy with subsequent autologous stem cell transplantation compared to standard chemotherapy (4 x DexaBEAM vs. 2 x DexaBEAM + BEAM and SCT).
(publication on the HD-R1 study

HD-R2

The HD-R2 evaluated whether relapsed Hodgkin lymphoma patients benefit from an intensified chemotherapy regimen before autologous stem stell transplantation (2 x DHAP + BEAM and SCT vs. 2 x DHAP + single HDCT + BEAM and SCT).
(publication on the HD-R2 study

AVD Rev trial

The aim of the AVD Rev trial was to determine dose-limiting toxicities of lenalidomide in combination with adriamycin, vinblastine and dacarbazine in relapsed intermediate or advanced stage Hodgkin lymphoma patients aged between 60 and 75.

Ofatumumab

The Ofatumumab trial aimed to measure the efficacy of the fully human CD20 antibody Ofatumumab, based on the overall response rate (ORR), in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) . All patients in this one-arm phase II trial were administered ofatumumab once a week for 8 weeks in total. ORR was recorded three months after the last infusion of the antibody. Further aims were to document the state of remission after 3 and 12 months, as well as progression-free survival (PFS) and duration of response.
(publication on the Ofatumumab study)

Other phase I/II trials

PVAG trial

This multicenter phase 2 trial evaluated a polychemotherapy regimen including prednisone, vinblastine, doxorubicin and gemcitabine in older patients with newly diagnosed Hodgkin lymphoma.
(publication on the PVAG study

BACOPP trial

This multicenter phase II trial aimed to evaluate a polychemotherapeutic approach with bleomycin, doxorubicin cyclophosphamide, vincristine, procarbazine and prednisone in older patients with newly diagnosed Hodgkin lymphoma.
(publication on the BACOPP study)

RIPL trial

This multicenter phase II trial evaluated the efficacy of monotherapy with rituximab in NLPHL patients at stage IA without risk factors.
(publication on the RIPL study)

PROFE trial

The PROFE trial evaluated ovarian protection in women with advanced stage Hodgkin lymphoma who were being treated with escalated BEACOPP and GnRH analogues. The patients were randomized to receive either oral contraceptives or monthly GnRH analogues. The trial included hormonal level investigations in patients of both treatment groups.
(publication on the PROFE study)